Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799994 · ClinicalTrials.gov registry record
Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?
A clinical trial, sponsored by Wills Eye.
- Completed
- Registry status
- 23
- Enrollment target
NCT00799994: Completed study, sponsored by Wills Eye.
NCT00799994 is a clinical trial that has completed, run by Wills Eye. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799994 has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
A study to determine whether a patient's range of vision test results improve after their eye pressure is lowered by 30% or more by testing on a new machine called the Accumap and how to learn how much the Accumap's results change from one test to another within the same person. The investigators believe that Multifocal VEP readings (Accumap)(and therefore visual function and ganglion cell function) improve after acutely lowering intraocular pressure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-01 |
What the finished NCT00799994 record still lists
NCT00799994 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00799994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799994 about?
NCT00799994 is a clinical study titled "Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?". A study to determine whether a patient's range of vision test results improve after their eye pressure is lowered by 30% or more by testing on a new machine called the Accumap and how to learn how much the Accumap's results change from one test to another within the same person. The investigators b...
What is the current status of trial NCT00799994?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2004-10. Estimated completion is 2007-01.
Who is sponsoring clinical trial NCT00799994?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia